Methamphetamine-associated HF (MethHF) prevalence is increasing and is associated with significant morbidity, according to a review published in Heart. Veena Manja, PhD, and colleagues examined data from 21 studies and found that MethHF affects diverse groups, with a predominance in males. Compared with non-methamphetamine related HF, MethHF was associated with significant morbidity, including worse symptoms. Improved outcomes were seen in association with female sex, methamphetamine abstinence, and guideline-directed therapy.
